PDX Pharmaceuticals, Inc.
Publicly observedPortland, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Portland | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | PDX Pharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | VTX7JRKLC3F5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant5 Sept 2024Publicly observed
NIH SBIR/STTR award: Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
USD 89,348.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant6 Jul 2023Publicly observed
NIH SBIR/STTR award: PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
USD 1,288,251.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.